B. Sadler

发表

Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers

Lynn R. Webster, J. Violin, L. Webster, 2014, PAIN®.

Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride.

B. Sadler, A. Jeffcoat, J. Hill, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children.

L. Aarons, B. Sadler, J. Sjövall, 2011, British journal of anaesthesia.

Clinical Pharmacology and Pharmacokinetics of Amprenavir

B. Sadler, D. Stein, 2002, The Annals of pharmacotherapy.

Aripiprazole Lauroxil

L. Citrome, M. Hard, B. Sadler, 2017, Journal of clinical psychopharmacology.

Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model

P. Weiden, L. V. von Moltke, M. Hard, 2017, CNS Drugs.

Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males

B. Sadler, D. Brophy, R. Polk, 2001, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Pharmacodynamics of MN-221, a Novel, Highly Selective Beta2-Adrenergic Agonist for Treatment of Acute Chronic Obstructive Pulmonary Disease

A. Dunton, B. Sadler, J. Bosley, 2010 .

Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking.

B. Sadler, A. Jeffcoat, J. Hill, 1989, Drug metabolism and disposition: the biological fate of chemicals.

First Clinical Experience With TRV130: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

J. Violin, C. Cowan, M. Lark, 2014, Journal of clinical pharmacology.

Pharmacokinetic Interaction between Ketoconazole and Amprenavir after Single Doses in Healthy Men

A. Pastor, B. Sadler, M. Crouch, 1999, Pharmacotherapy.

Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine

B. Sadler, H. Chambers, B. Lee, 1996, Clinical pharmacology and therapeutics.

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

S. Piscitelli, B. Sadler, J. Brandt, 2015, British journal of clinical pharmacology.

The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

Yan-Ling He, B. Sadler, R. Sabo, 2007, Clinical pharmacokinetics.

Oliceridine, a Novel G Protein–Biased Ligand at the μ‐Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic Model

D. Soergel, B. Sadler, F. Skobieranda, 2018, Journal of clinical pharmacology.

Metabolism, disposition, and kinetics of delta‐9‐tetrahydrocannabinol in men and women

B. Sadler, M. Wall, M. Pérez-Reyes, 1983, Clinical pharmacology and therapeutics.

Drug level monitoring in a double-blind multicenter trial: false-positive zidovudine measurements in AIDS clinical trials group protocol 019

P. Volberding, B. Sadler, D. Krogstad, 1991, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil

L. V. von Moltke, M. Hard, B. Sadler, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Oliceridine (TRV130), a Novel G Protein–Biased Ligand at the μ‐Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model

D. Soergel, B. Sadler, F. Skobieranda, 2018, Journal of clinical pharmacology.

agonism of the l-opioid receptor by TRV 130 increases analgesia and reduces on-target adverse effects versus morphine : A randomized , double-blind , placebo-controlled , crossover study in healthy

J. Violin, L. Webster, M. Lark, 2014 .

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

K. Bhalla, M. Albitar, J. Lancet, 2006 .

Pharmacokinetic Interaction between Amprenavir and Clarithromycin in Healthy Male Volunteers

A. Pastor, B. Sadler, D. Brophy, 2000, Antimicrobial Agents and Chemotherapy.

Atovaquone Suspension in HIV‐Infected Volunteers: Pharmacokinetics, Pharmacodynamics, and TMP‐SMX Interaction Study

R. Davey, J. Kovacs, M. Polis, 1999, Pharmacotherapy.

Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing

B. Sadler, D. Stein, Y. Lou, 2001, Antimicrobial Agents and Chemotherapy.

Prolonged, But Not Diminished, Zidovudine Absorption Induced by a High‐Fat Breakfast

R. Reichman, B. Sadler, M. Shelton, 1994, Pharmacotherapy.

Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and Ritonavir

B. Sadler, D. Stein, M. Sale, 2002, Antimicrobial Agents and Chemotherapy.

In Vivo Effect of α1-Acid Glycoprotein on Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Protease Inhibitor

B. Sadler, D. Stein, Y. Lou, 2001, Antimicrobial Agents and Chemotherapy.

Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults

B. Sadler, W. Symonds, N. Roskell, 1999, Antimicrobial Agents and Chemotherapy.

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents.

B. Sadler, G. Painter, J. Rooney, 1996, Antiviral research.

Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers

B. Sadler, D. Stein, Y. Lou, 2001, AIDS.

Metabolic Disposition and Pharmacokinetics of [14C]‐Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV‐1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects

B. Sadler, R. Polk, T. Kerkering, 2001, Journal of clinical pharmacology.

Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir

R. Haubrich, B. Sadler, J. Eron, 2001, Antimicrobial Agents and Chemotherapy.

Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function

B. Sadler, D. Stein, Y. Lou, 2000, Antimicrobial Agents and Chemotherapy.

Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529

Samit R. Joshi, B. Sadler, R. Bertz, 2016, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Azithromycin Administered Alone and with Atovaquone in Human Immunodeficiency Virus-Infected Children

B. Sadler, R. Yogev, J. Unadkat, 1999, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans.

B. Sadler, A. Jeffcoat, J. Hill, 1992, Drug metabolism and disposition: the biological fate of chemicals.

Plasma levels of methamphetamine after smoking of methamphetamine hydrochloride.

B. Sadler, A. Jeffcoat, J. Hill, 1990, NIDA research monograph.

Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria.

B. Sadler, C. Canfield, A. Sabchareon, 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Phase I Safety and Pharmacokinetics Study of Micronized Atovaquone in Human Immunodeficiency Virus-Infected Infants and Children

B. Sadler, R. Yogev, J. Moye, 1998, Antimicrobial Agents and Chemotherapy.

Developmental toxicity of 1,1,1-trichloroethane in CD rats.

L. Birnbaum, C. Price, M. Marr, 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology.

Crowdsourced Asparagus Urinary Odor Population Kinetics

Lei Zhang, P. H. van der Graaf, B. Sadler, 2017, CPT: pharmacometrics & systems pharmacology.

Metabolism, disposition and excretion of [14C]melamine in male Fischer 344 rats.

R. Kraska, B. Sadler, A. Jeffcoat, 1983, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

METABOLISM, DISPOSITION AND PHARMACOKINETICS OF DELTA-9-TETRAHYDROCANNABINOL IN MALE AND FEMALE SUBJECTS*

B. Sadler, M. Wall, H. Taylor, 1984 .

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia

B. Sadler, Lei Sun, B. Rege, 2021, Journal of clinical pharmacology.

Nucleoside Analog 1592U89 and Human Immunodeficiency Virus Protease Inhibitor 141W94 Are Synergistic In Vitro

J. Bilello, G. Drusano, B. Sadler, 1998, Antimicrobial Agents and Chemotherapy.